These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 520653)

  • 21. Inpatient management of gout in a New Zealand hospital: a retrospective audit.
    Kennedy NJ; Healy PJ; Harrison AA
    Int J Rheum Dis; 2016 Feb; 19(2):205-10. PubMed ID: 25873399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperuricemia and gout.
    Sloan RW
    J Fam Pract; 1982 May; 14(5):923-6, 930-1, 934. PubMed ID: 7042900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of gout.
    Cohen MG
    Intern Med J; 2011 Jan; 41(1a):70-1. PubMed ID: 21265967
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical inquiry. Are serum uric acid levels always elevated in acute gout?
    Leiszler M; Poddar S; Fletcher A
    J Fam Pract; 2011 Oct; 60(10):618-20. PubMed ID: 21977490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The current state of care in gout: Addressing the need for better understanding of an ancient disease.
    Zychowicz ME; Pope RS; Graser E
    J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing gout: there's more we can do.
    Mead T; Arabindoo K; Smith B
    J Fam Pract; 2014 Dec; 63(12):707-13. PubMed ID: 25486309
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihyperuricemic properties of amflutizole in gout.
    Wortmann RL; Ridolfo AS; Lightfoot RW; Fox IH
    J Rheumatol; 1985 Jun; 12(3):540-3. PubMed ID: 3900392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 32. Updates in the management of gout.
    Keith MP; Gilliland WR
    Am J Med; 2007 Mar; 120(3):221-4. PubMed ID: 17349440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [How to treat hyperuricemia and gout attacks in compensated kidney failure?].
    Gröbner W
    Dtsch Med Wochenschr; 2002 Mar; 127(11):576. PubMed ID: 11894180
    [No Abstract]   [Full Text] [Related]  

  • 35. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of gout: where are we now?
    Richette P
    Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i1-i3. PubMed ID: 29272509
    [No Abstract]   [Full Text] [Related]  

  • 37. Low omega-3 fatty acid levels associate with frequent gout attacks: a case control study.
    Abhishek A; Valdes AM; Doherty M
    Ann Rheum Dis; 2016 Apr; 75(4):784-5. PubMed ID: 26715654
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hyperuricemia: a laboratory finding needing treatment?].
    Keller C
    Verh Dtsch Ges Inn Med; 1990; 96():188-92. PubMed ID: 2092438
    [No Abstract]   [Full Text] [Related]  

  • 39. Rational therapy for hyperuricaemia.
    Monteagudo FS; Meyers OL
    S Afr Med J; 1986 Mar; 69(6):338. PubMed ID: 3961614
    [No Abstract]   [Full Text] [Related]  

  • 40. Preliminary studies with azapropazone in gout and hyperuricaemia.
    Thomas AL; Majoos FL; Nuki G
    Eur J Rheumatol Inflamm; 1983; 6(2):149-54. PubMed ID: 6673978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.